Procept BioRobotics reports Q4 EPS (35c), consensus (35c)

Reports Q4 revenue $68.24M, consensus $66.79M. “In pursuit of our long-term vision to transform the global treatment of BPH and ultimately build a global urology company, 2024 was a productive year for PROCEPT in two key areas,” said Reza Zadno, CEO. “First, in August, we received FDA 510(k) clearance of our next-generation platform – the HYDROS Robotic System. This was a pivotal moment for the Company as HYDROS represents the first significant technological advancement compared to the AquaBeam(R) system. Second, we received FDA-IDE approval to initiate WATER IV PCa, a pivotal randomized clinical study for prostate cancer. As we enter 2025, we believe there are several positive factors that will enable us to continue to pursue our long-term growth strategy while continuing a disciplined approach on our path to profitability.”